Tech Company Financing Transactions
Recursion Pharmaceuticals Funding Round
Recursion Pharmaceuticals closed a $121 million Series C venture capital round on 7/16/2019. Investors included Baillie Gifford, AME Cloud Ventures and CRV.
Transaction Overview
Company Name
Announced On
7/16/2019
Transaction Type
Venture Equity
Amount
$121,000,000
Round
Series C
Investors
Proceeds Purpose
The new financing will support Recursion's continued build-out of its machine learning-enabled drug discovery platform alongside new capabilities designed to radically accelerate new chemical entity chemistry and predict safety pharmacology.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
41S Rio Grande St.
Salt Lake City, UT 84101
USA
Salt Lake City, UT 84101
USA
Phone
Website
Email Address
Overview
At Recursion, we are Making Rare Diseases History. We combine innovative biological science with advanced computational algorithms to discover new therapeutic opportunities for rare genetic diseases.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/16/2019: Orchestra BioMed venture capital transaction
Next: 7/16/2019: Lendbuzz venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs